Why the study?
Does an implantable cardioverter defibrillator improve quality of life compared to antiarrhythmic drugs in patients with serious ventricular arrhythmias?
Does an implantable cardioverter defibrillator improve quality of life compared to antiarrhythmic drugs in patients with serious ventricular arrhythmias?
Answers are grounded in this paper and cite their sources.
In survivors of serious ventricular arrhythmias, ICD and AAD therapies are associated with similar quality of life outcomes at 1 year, though device shocks and medication adverse symptoms negatively impact QoL.
BACKGROUND: Implantable cardioverter defibrillator (ICD) use reduces mortality in patients with serious ventricular arrhythmias compared with antiarrhythmic drug (AAD) use. However, the relative impact of these therapies on self-perceived quality of life (QoL) is unknown. METHODS AND RESULTS: Three self-administered instruments were used to measure generic and disease-specific QoL in Antiarrhythmics Versus Implantable Defibrillators trial participants. Generalized linear models were used to assess the relationships between self-perceived QoL and treatment (AAD versus ICD) and adverse symptoms and ICD shocks. To minimize the impact of missing data, only patients surviving 1 year were included in the primary analyses. Baseline characteristics among QoL participants (n=905) and nonparticipants (n=111) were similar, but participants who survived 1 year (n=800) were healthier at baseline than nonsurvivors (n=105). Of the 800 patients in the primary analysis, characteristics of those randomized to AAD (n=384) versus ICD (n=416) were similar. Overall, ICD and AAD use were associated with similar alterations in QoL. The development of sporadic shocks and adverse symptoms were each associated with reduced physical functioning and mental well-being and increased concerns among ICD recipients, whereas development of adverse symptoms was associated with reduced physical functioning and increased concerns among AAD recipients. CONCLUSIONS: ICD and AAD therapy are associated with similar alterations in self-perceived QoL over 1-year follow-up. Adverse symptoms were associated with reduced self-perceived QoL in both groups, and sporadic shocks were associated with reduced QoL in ICD recipients.
No takes yet. Share an insight, caveat, or question.
Schron et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: